Sentences with phrase «hepatitis b»

Even legal instruments, like cuticle cutters and scissors, have the potential to transmit staph infections, hepatitis B and C, and, yes, HIV if they re contaminated with even microscopic drops of blood from an infected person, says Sonia Badreshia - Bansal, MD, a dermatologist in private practice in Danville, California.

And of course, any procedure involving needles poses other risks, such as contracting tetanus, hepatitis B, and hepatitis C if those needles are contaminated.

In another study, 40 medical students who tested negative for hepatitis B antibodies were randomly assigned to write about either their traumatic experiences or a neutral topic, and then were given a hepatitis B vaccine.

The CDC reported in 2010 that a type of liver cancer called hepatocellular carcinoma (HCC) was on the rise and that chronic hepatitis B and C infections accounted for an estimated 78 % of HCC cases worldwide.

People who already have chronic hepatitis B are at risk for becoming infected with a second virus, hepatitis D, also called delta hepatitis.

«It makes hepatitis B worse by far even when you treat the original condition,» Dr. Dieterich says.

If you've had the hepatitis B vaccine, you should be protected from catching the virus and later passing it on to your child.

The most common cause of hepatitis B transmission globally is mother to infant, Dr. Dieterich says.

There are 350 million individuals infected with the hepatitis B virus who are begging for a cure and need us to keep trying.

Earlier, Alter had participated in the discovery of the hepatitis B virus.

As our aim was to indicate general tissue specific carcinogenic properties, we used all the known subtypes of these cancers, including (1) hyper mutated and non-hypermutated colon cancers; (2) lung adenocarcinomas, large cell carcinomas, and squamous cell carcinomas (3) HER2 positive, basal, luminal A and luminal B breast cancers; and (4) hepatitis B or hepatitis C, cirrhosis or other agent causing hepatocellular carcinoma data.

Those breakthroughs include the development of new screening methods to search for effective drugs, new ways to treat hepatitis B using different approaches to shut down the virus, a new blood biomarker that aids in the early detection of liver cancer, and a promising drug that selectively kills liver cancer cells in animal studies.

Infection with hepatitis B and C viruses, for example, does not kill liver cells directly.

About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation's leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy.

The student group, which is the local chapter of a national organization, serves the local Asian / Pacific Islander American communities by conducting free health screenings at various community centers for diabetes, vision impairment, and hypertension, as well as hepatitis B and C, which disproportionately affect people of Asian descent.

«For more than half a century, Dr. London has represented the very best in a doctor and scientist — sincere compassion and outstanding research to advance the cause of and cure for hepatitis B infection,» said Timothy Block, Ph.D., president and co-founder of the Baruch S. Blumberg Institute and the Hepatitis B Foundation.

The professorship is named in honor of W. Thomas London, M.D., in recognition of his transformational contributions to the discovery of the hepatitis B virus and his unwavering commitment to the elimination of this devastating liver disease, which kills nearly 1 million people each year.

, serves the local Asian / Pacific Islander American communities by conducting free health screenings at various community centers for diabetes, vision impairment, and hypertension, as well as hepatitis B and C, which disproportionately affect people of Asian descent.

DOYLESTOWN, Pa. (March 2015)-- The Baruch S. Blumberg Institute (www.blumberginstitute.org) has recruited a new team of nationally renowned scientists to focus exclusively on research to develop a cure for hepatitis B, a move that nearly triples its research capacity and has created the largest concentration of nonprofit scientists focusing solely on hepatitis B and liver cancer in the United States.

About the Hepatitis B Foundation: Headquartered in Doylestown, Pa., the Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy.

He's currently focused on reformulating drugs called nucleoside analog drugs, which have been used to treat HIV, hepatitis B, and pancreatic cancer.

Serving as vice president of the Hepatitis B Foundation Board of Directors, Dr. London is an internationally renowned physician - scientist who has dedicated his entire professional career to the study of hepatitis B and to the care of those who live with this chronic liver disease.

Baruch S. Blumberg, M.D., Ph.D., inventor of the original hepatitis B vaccine, was inducted in 1993.

In the early 1960s, Dr. London was a crucial member of the research team that first identified the hepatitis B virus and then developed first the blood test to detect infection and then the vaccine.

The revolutionary device can also be used to detect hepatitis B in just 2 hours.

The Australia antigen was named the hepatitis B virus, as a hepatitis A virus already had been identified.

His long - term collaboration with Dr. Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus, led to breakthrough epidemiological, clinical, and virological studies of hepatitis B and its link to primary liver cancer, or hepatocellular carcinoma (HCC).

«This is an incredibly exciting time in hepatitis B research, with the field poised to develop a cure.

The researchers will build upon recent discoveries that have accelerated the momentum for developing a cure for hepatitis B and liver cancer.

He suggested that these vectors might also create an immune response that could be used more broadly to attack tuberculosis, malaria, hepatitis B, and other viral and nonviral diseases.

«The years that we all have spent working towards a cure for hepatitis B have laid the groundwork for this final phase,» said Block.

He showed that chronic hepatitis B infections were endemic among patients in hemodialysis units, while staff members who became infected developed acute hepatitis.

DOYLESTOWN, Pa. (October 2015)-- The Baruch S. Blumberg Institute, established by the Hepatitis B Foundation to fulfill its research mission, is pleased to announce the creation of the W. Thomas London Distinguished Professorship and its inaugural presentation to leading hepatitis B researcher Dr. Ju - Tao Guo.

The World Health Organization estimates that more than 240 million people worldwide are chronically infected with the hepatitis B virus.

«The fact that Dr. Tim Block and other world - class scientists have chosen to join the Blumberg Institute in its drive to find a cure for hepatitis B speaks volumes about the Institute's cutting - edge science and potential to impact global health,» said Wayne Yetter, former president and CEO of the multinational pharmaceutical company Novartis U.S. and a recent addition to the Hepatitis B Foundation's Board of Directors.

Dr. Guo is a leader in the field of hepatitis B research and worked closely with Dr. London and other leading hepatitis scientists at the Fox Chase Cancer Center prior to joining the Blumberg Institute.

About the Hepatitis B Foundation: Headquartered in Doylestown, Pa., the Hepatitis B Foundation was founded in 1991 and is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy.

«We are committing everything we have, every resource at our disposal, to developing the therapies that will improve the lives of the millions of people worldwide who live with the hepatitis B virus every day, as well as the risk of dying prematurely from its most fatal consequence, liver cancer.»

Humans and chimpanzees, for instance, have slightly different versions of the hepatitis B virus, both of which likely mutated from a version that infected their shared ancestor more than four million years ago.

The interface between hepatitis B virus capsid proteins affects self - assembly, pregenomic RNA packaging, and reverse transcription.

Alcohol plus hepatitis B raises cholesterol.

More than 350 million individuals suffer from chronic infection with hepatitis B virus (HBV), including more than 1.25 million Americans.

Transfusion medicine is linked to multiple viral infections, including persistent viruses like HIV and hepatitis B and C, as well as emerging arboviral infections like West Nile virus, Zika virus, and others.

The Warren Alpert Foundation Prize has also recognized recipients for discoveries that have impacted a wide spectrum of diseases, including asthma, breast cancer, H. pylori infection, hepatitis B and HIV / AIDS.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria

The research center was renamed in 2013 to honor Baruch S. Blumberg, the man who won the Nobel Prize for his discovery of the hepatitis B virus.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Through powerful and lasting partnerships, the Baruch S. Blumberg Institute seeks to find cures for chronic hepatitis B, develop early detection biomarkers for liver disease and liver cancer, train future researchers, nurture biotechnology entrepreneurship, and provide information and support to those affected by chronic hepatitis worldwide.

The research center was renamed in 2013 to honor Baruch S. Blumberg who won the Nobel Prize for his discovery of the hepatitis B virus.

«Dr. Pestell's recruitment will go a long way toward helping us achieve our goal of finding a cure for diseases associated with hepatitis B and liver cancer,» said Timothy Block, Ph.D., president of the Hepatitis B Foundation, the Baruch S. Blumberg Institute, and the Pennsylvania Biotechnology Center, where both are headquartered.